Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer. This is an ...
Exploration of the utility of alkaline phosphatase level (ALP) as a prognostic factor in patients with metastatic castrate resistant prostate cancer (mCRPC) receiving prechemotherapy abiraterone ...
Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse ...
Laser Prostatectomy In a series of 25 men, radiographic evidence correctly predicted significant prostate cancer in all patients on final pathology. Performing radical prostatectomy (RP) based solely ...
J. Naga Raju Guntupalli, Sarita Padala, A.V. Ramana Murty Gummuluri, Ravi Kumar Muktineni, Seetharami Reddy Byreddy, Lakshminarayana Sreerama, Prema Chand Kedarisetti ...
A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...
Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Dr. Glenn Bauman, Scientist at LHSCRI and Radiation Oncologist at London Health Sciences Centre (LHSC), stands in front of the positron emission tomography (PET) scanner. LONDON, ON – A multicentre ...
Some high-grade prostate cancers, such as intraductal carcinoma of the prostate, are not clearly visible on PSMA PET. For patients with intraductal carcinoma of the prostate (IDC-P), prostate-specific ...
PERTH, Australia – Melbourne-based Telix Pharmaceuticals Ltd. has submitted its first new drug application to the FDA for TLX591-CDx, a radiopharmaceutical targeting prostate-specific membrane antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback